All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Non relapse or transplant related mortality · participants with haematological malignancies
BMT showed no clear difference in non relapse or transplant related mortality compared with PBSCT (high certainty).
1 finding from 1 review
Chronic GVHD (extensive) · participants with haematological malignancies
BMT probably leads to lower extensive chronic GvHD compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GvHD III to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD III to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Chronic GvHD overall · participants with haematological malignancies
BMT probably leads to lower chronic GvHD overall compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GVHD II to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD II to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
CAT score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
2 findings from 1 review
Dyspnoea ‐ change in mMRC Scale 0 to 4. Lower is better and 1 unit is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsf · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsd · patients with chronic obstructive pulmonary disease
1 finding from 1 review
General health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality, allogeneic BMT · immunosuppressed adults with cancer
Influenza vaccine showed no clear difference in all‐cause mortality, allogeneic BMT compared with no vaccine (low certainty).
1 finding from 1 review
All‐cause mortality, allogeneic BMT · immunosuppressed adults with cancer
Adjuvanted influenza vaccine showed no clear difference in all‐cause mortality, allogeneic BMT, compared with non‐adjuvanted influenza vaccine (low certainty).
1 finding from 1 review